ARG SAB Meeting 5/24
The ARG SAB (Strategic Advisory Board) regularly convenes to discuss emerging trends and issues in rare diseases, adding to the […]
Does Your CRO Understand the Ultimate trial goal?
ARG Patient-Centricity Nurtures relationships with rare disease advocacy groups Innovates with our “Study champion” model Understands and addresses human factors ARG’s primary goal is to improve and prolong the lives of the people affected by rare […]
Quarterly Q & A with CEO Paul Bishop and President Lyle Camblos
Each quarter, ARG CEO Paul Bishop and President Lyle Camblos will share their thoughts and responses concerning relevant company and […]
ARG Presence at Alliance For Regenerative Medicine Annual Dinner & Legislative Fly-In
Jeff Cazeault, Head of Business Development at ARG, is in Washington, DC to attend the Alliance for Regenerative Medicine Annual […]
Is your CRO tailor-made to meet trial requirements?
ARG Flexibility Adjusts based on unique rare disease study conditions Addresses challenges via anticipation and adaptation Collaborates to further and […]